{"id":370,"date":"2014-05-06T10:37:08","date_gmt":"2014-05-06T08:37:08","guid":{"rendered":"https:\/\/mic-site.labiux.com\/uncategorized\/grindeks-apgrozijums-pern-audzis-par-1\/"},"modified":"2026-10-06T06:29:26","modified_gmt":"2026-10-06T03:29:26","slug":"grindeks-apgrozijums-pern-audzis-par-1","status":"publish","type":"post","link":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/","title":{"rendered":"&#8220;Grindeks&#8221; apgroz\u012bjums p\u0113rn audzis par 1%"},"content":{"rendered":"<div class=\"wp-block-labiux-legacy-html legacy-content\">\n<p>AS &#8220;Grindeks&#8221; 30.apr\u012bl\u012b &#8220;NASDAQ OMX Riga&#8221; bir\u017e\u0101 iesniegtie 2013.gada revid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna apgroz\u012bjums p\u0113rn bijis 118,5 miljoni eiro, kas ir par 0,8 miljoniem eiro jeb par 1% vair\u0101k k\u0101 2012. gad\u0101. Koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2013. gad\u0101 bijusi 13,4 miljoni eiro, zi\u0146o uz\u0146\u0113muma p\u0101rst\u0101vji.<\/p>\n<p>Bruto pe\u013c\u0146as rentabilit\u0101te 2013. gad\u0101 bijusi 60%, savuk\u0101rt t\u012br\u0101s pe\u013c\u0146as rentabilit\u0101te -11,3%. 2013. gad\u0101 koncerna sara\u017eot\u0101 produkcija eksport\u0113ta uz 59 pasaules valst\u012bm, kopum\u0101 par 112,4 miljoniem eiro, kas ir par 1,2 miljoniem eiro jeb par 1,1% vair\u0101k k\u0101 2012. gad\u0101.<\/p>\n<p>&#8220;Grindeks&#8221; gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms p\u0113rn sasniedzis 100,3 miljonus eiro, kas ir par 0,8 miljoniem eiro jeb par 1% liel\u0101ks k\u0101 gadu iepriek\u0161. Krievijas, p\u0101r\u0113jo NVS valstu un Gruzijas p\u0101rdo\u0161anas apjoms p\u0113rn sasniedzis 86,7 miljonus eiro, kas ir par 0,9 miljoniem eiro jeb 1% vair\u0101k k\u0101 2012. gad\u0101. Savuk\u0101rt gatavo z\u0101\u013cu formu p\u0101rdo\u0161anas apjoms Baltijas un cit\u0101s Eiropas valst\u012bs sasniedzis 13,6 miljonus eiro, kas ir par 0,1 miljoniem euro jeb 0,4% maz\u0101k k\u0101 2012. gad\u0101.<\/p>\n<p>Akt\u012bvo farmaceitisko vielu p\u0101rdo\u0161anas apjoms p\u0113rn sasniedzis 18 miljonus eiro, kas ir par 0,1 miljoniem eiro jeb 0,4% maz\u0101k k\u0101 2012. gad\u0101. Kop\u0101 &#8220;Grindeks&#8221; ra\u017eo 25 akt\u012bv\u0101s farmaceitisk\u0101s vielas.<\/p>\n<p>Uz\u0146\u0113muma valdes priek\u0161s\u0113d\u0113t\u0101js Juris Bundulis pag\u0101ju\u0161\u0101 gada apgroz\u012bjumu un pe\u013c\u0146u v\u0113rt\u0113 k\u0101 iev\u0113rojamus sasniegumus, \u0146emot v\u0113r\u0101 s\u012bvo konkurenci farm\u0101cijas tirg\u016b. \u0160ogad uz\u0146\u0113mums iecer\u0113jis pilnveidot savu darb\u012bbas modeli, kas iepriek\u0161 bija v\u0113rsts galvenok\u0101rt uz visvair\u0101k p\u0101rdotajiem produktiem, un turpm\u0101k uzman\u012bbu vair\u0101k koncentr\u0113t uz pla\u0161\u0101ku produktu un pakalpojumu kl\u0101stu. &#8220;Grindeks&#8221; ar\u012b turpm\u0101k pl\u0101no gan att\u012bst\u012bt produktu portfeli, gan turpin\u0101t jaunu tirgu apguvi.<\/p>\n<p>El\u012bna Badune<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>AS &#8220;Grindeks&#8221; 30.apr\u012bl\u012b &#8220;NASDAQ OMX Riga&#8221; bir\u017e\u0101 iesniegtie 2013.gada revid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna apgroz\u012bjums p\u0113rn bijis 118,5 miljoni eiro, kas ir par 0,8 miljoniem eiro jeb par 1% [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":11814,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"mic_cinema_image":0,"mic_focus":"","mic_cinema_focus":"","footnotes":"","_labiux_rail":0},"categories":[70,76,7],"tags":[],"mic_flag":[],"class_list":["post-370","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-farmacijas-zinas","category-jaunakie-raksti","category-statistika"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.4 - aioseo.com -->\n\t<meta name=\"description\" content=\"AS &quot;Grindeks&quot; 30.apr\u012bl\u012b &quot;NASDAQ OMX Riga&quot; bir\u017e\u0101 iesniegtie 2013.gada revid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna apgroz\u012bjums p\u0113rn bijis 118,5 miljoni eiro, kas ir par 0,8 miljoniem eiro jeb par 1% vair\u0101k k\u0101 2012. gad\u0101. Koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2013. gad\u0101 bijusi 13,4 miljoni eiro, zi\u0146o uz\u0146\u0113muma p\u0101rst\u0101vji.Bruto pe\u013c\u0146as rentabilit\u0101te 2013.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"admin\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.4\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"\u201cGrindeks\u201d apgroz\u012bjums p\u0113rn audzis par 1% - Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta property=\"og:description\" content=\"AS &quot;Grindeks&quot; 30.apr\u012bl\u012b &quot;NASDAQ OMX Riga&quot; bir\u017e\u0101 iesniegtie 2013.gada revid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna apgroz\u012bjums p\u0113rn bijis 118,5 miljoni eiro, kas ir par 0,8 miljoniem eiro jeb par 1% vair\u0101k k\u0101 2012. gad\u0101. Koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2013. gad\u0101 bijusi 13,4 miljoni eiro, zi\u0146o uz\u0146\u0113muma p\u0101rst\u0101vji.Bruto pe\u013c\u0146as rentabilit\u0101te 2013.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Grindex-logo.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Grindex-logo.jpg\" \/>\n\t\t<meta property=\"og:image:width\" content=\"660\" \/>\n\t\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2014-05-06T08:37:08+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-10-06T03:29:26+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"\u201cGrindeks\u201d apgroz\u012bjums p\u0113rn audzis par 1% - Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta name=\"twitter:description\" content=\"AS &quot;Grindeks&quot; 30.apr\u012bl\u012b &quot;NASDAQ OMX Riga&quot; bir\u017e\u0101 iesniegtie 2013.gada revid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna apgroz\u012bjums p\u0113rn bijis 118,5 miljoni eiro, kas ir par 0,8 miljoniem eiro jeb par 1% vair\u0101k k\u0101 2012. gad\u0101. Koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2013. gad\u0101 bijusi 13,4 miljoni eiro, zi\u0146o uz\u0146\u0113muma p\u0101rst\u0101vji.Bruto pe\u013c\u0146as rentabilit\u0101te 2013.\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Grindex-logo.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/grindeks-apgrozijums-pern-audzis-par-1\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/statistika\\\/#listItem\",\"name\":\"Statistika\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/statistika\\\/#listItem\",\"position\":2,\"name\":\"Statistika\",\"item\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/statistika\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/grindeks-apgrozijums-pern-audzis-par-1\\\/#listItem\",\"name\":\"&#8220;Grindeks&#8221; apgroz\\u012bjums p\\u0113rn audzis par 1%\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/grindeks-apgrozijums-pern-audzis-par-1\\\/#listItem\",\"position\":3,\"name\":\"&#8220;Grindeks&#8221; apgroz\\u012bjums p\\u0113rn audzis par 1%\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/statistika\\\/#listItem\",\"name\":\"Statistika\"}}]},{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/grindeks-apgrozijums-pern-audzis-par-1\\\/#newsarticle\",\"name\":\"\\u201cGrindeks\\u201d apgroz\\u012bjums p\\u0113rn audzis par 1% - Medikamentu Inform\\u0101cijas Centrs\",\"headline\":\"&#8220;Grindeks&#8221; apgroz\\u012bjums p\\u0113rn audzis par 1%\",\"author\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/wp-content\\\/uploads\\\/Grindex-logo.jpg\",\"width\":660,\"height\":330},\"datePublished\":\"2014-05-06T10:37:08+03:00\",\"dateModified\":\"2026-10-06T06:29:26+03:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/grindeks-apgrozijums-pern-audzis-par-1\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/grindeks-apgrozijums-pern-audzis-par-1\\\/#webpage\"},\"articleSection\":\"Farm\\u0101cija, Jaun\\u0101kie raksti, Statistika\",\"dateline\":\"Published on May 6, 2014.\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\",\"name\":\"Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Farm\\u0101cijas nozares port\\u0101ls farmaceitiem un \\u0101rstiem. Zi\\u0146as, normat\\u012bvie akti, pas\\u0101kumi un t\\u0101l\\u0101kizgl\\u012bt\\u012bba vienuviet kop\\u0161 2001. gada.\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/grindeks-apgrozijums-pern-audzis-par-1\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/be3221a6fac131657111728b4d912a877ec158b123d5db3afef3bd8a59784ece?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"admin\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/grindeks-apgrozijums-pern-audzis-par-1\\\/#webpage\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/grindeks-apgrozijums-pern-audzis-par-1\\\/\",\"name\":\"\\u201cGrindeks\\u201d apgroz\\u012bjums p\\u0113rn audzis par 1% - Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"AS \\\"Grindeks\\\" 30.apr\\u012bl\\u012b \\\"NASDAQ OMX Riga\\\" bir\\u017e\\u0101 iesniegtie 2013.gada revid\\u0113tie finan\\u0161u p\\u0101rskati liecina, ka koncerna apgroz\\u012bjums p\\u0113rn bijis 118,5 miljoni eiro, kas ir par 0,8 miljoniem eiro jeb par 1% vair\\u0101k k\\u0101 2012. gad\\u0101. Koncerna neto pe\\u013c\\u0146a, kas attiecin\\u0101ma uz m\\u0101tes sabiedr\\u012bbas akcion\\u0101riem, 2013. gad\\u0101 bijusi 13,4 miljoni eiro, zi\\u0146o uz\\u0146\\u0113muma p\\u0101rst\\u0101vji.Bruto pe\\u013c\\u0146as rentabilit\\u0101te 2013.\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/grindeks-apgrozijums-pern-audzis-par-1\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/wp-content\\\/uploads\\\/Grindex-logo.jpg\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/grindeks-apgrozijums-pern-audzis-par-1\\\/#mainImage\",\"width\":660,\"height\":330},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/grindeks-apgrozijums-pern-audzis-par-1\\\/#mainImage\"},\"datePublished\":\"2014-05-06T10:37:08+03:00\",\"dateModified\":\"2026-10-06T06:29:26+03:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\",\"name\":\"Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Farm\\u0101cijas nozares port\\u0101ls farmaceitiem un \\u0101rstiem. Zi\\u0146as, normat\\u012bvie akti, pas\\u0101kumi un t\\u0101l\\u0101kizgl\\u012bt\\u012bba vienuviet kop\\u0161 2001. gada.\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"\u201cGrindeks\u201d apgroz\u012bjums p\u0113rn audzis par 1% - Medikamentu Inform\u0101cijas Centrs","description":"AS \"Grindeks\" 30.apr\u012bl\u012b \"NASDAQ OMX Riga\" bir\u017e\u0101 iesniegtie 2013.gada revid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna apgroz\u012bjums p\u0113rn bijis 118,5 miljoni eiro, kas ir par 0,8 miljoniem eiro jeb par 1% vair\u0101k k\u0101 2012. gad\u0101. Koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2013. gad\u0101 bijusi 13,4 miljoni eiro, zi\u0146o uz\u0146\u0113muma p\u0101rst\u0101vji.Bruto pe\u013c\u0146as rentabilit\u0101te 2013.","canonical_url":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/#listItem","position":1,"name":"Home","item":"https:\/\/farmacija-mic.lv\/en\/","nextItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/statistika\/#listItem","name":"Statistika"}},{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/statistika\/#listItem","position":2,"name":"Statistika","item":"https:\/\/farmacija-mic.lv\/category\/statistika\/","nextItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/#listItem","name":"&#8220;Grindeks&#8221; apgroz\u012bjums p\u0113rn audzis par 1%"},"previousItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/#listItem","position":3,"name":"&#8220;Grindeks&#8221; apgroz\u012bjums p\u0113rn audzis par 1%","previousItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/statistika\/#listItem","name":"Statistika"}}]},{"@type":"NewsArticle","@id":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/#newsarticle","name":"\u201cGrindeks\u201d apgroz\u012bjums p\u0113rn audzis par 1% - Medikamentu Inform\u0101cijas Centrs","headline":"&#8220;Grindeks&#8221; apgroz\u012bjums p\u0113rn audzis par 1%","author":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"publisher":{"@id":"https:\/\/farmacija-mic.lv\/en\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Grindex-logo.jpg","width":660,"height":330},"datePublished":"2014-05-06T10:37:08+03:00","dateModified":"2026-10-06T06:29:26+03:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/#webpage"},"isPartOf":{"@id":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/#webpage"},"articleSection":"Farm\u0101cija, Jaun\u0101kie raksti, Statistika","dateline":"Published on May 6, 2014."},{"@type":"Organization","@id":"https:\/\/farmacija-mic.lv\/en\/#organization","name":"Medikamentu Inform\u0101cijas Centrs","description":"Farm\u0101cijas nozares port\u0101ls farmaceitiem un \u0101rstiem. Zi\u0146as, normat\u012bvie akti, pas\u0101kumi un t\u0101l\u0101kizgl\u012bt\u012bba vienuviet kop\u0161 2001. gada.","url":"https:\/\/farmacija-mic.lv\/en\/"},{"@type":"Person","@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author","url":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/","name":"admin","image":{"@type":"ImageObject","@id":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/be3221a6fac131657111728b4d912a877ec158b123d5db3afef3bd8a59784ece?s=96&d=mm&r=g","width":96,"height":96,"caption":"admin"}},{"@type":"WebPage","@id":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/#webpage","url":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/","name":"\u201cGrindeks\u201d apgroz\u012bjums p\u0113rn audzis par 1% - Medikamentu Inform\u0101cijas Centrs","description":"AS \"Grindeks\" 30.apr\u012bl\u012b \"NASDAQ OMX Riga\" bir\u017e\u0101 iesniegtie 2013.gada revid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna apgroz\u012bjums p\u0113rn bijis 118,5 miljoni eiro, kas ir par 0,8 miljoniem eiro jeb par 1% vair\u0101k k\u0101 2012. gad\u0101. Koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2013. gad\u0101 bijusi 13,4 miljoni eiro, zi\u0146o uz\u0146\u0113muma p\u0101rst\u0101vji.Bruto pe\u013c\u0146as rentabilit\u0101te 2013.","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/farmacija-mic.lv\/en\/#website"},"breadcrumb":{"@id":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/#breadcrumblist"},"author":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"creator":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Grindex-logo.jpg","@id":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/#mainImage","width":660,"height":330},"primaryImageOfPage":{"@id":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/#mainImage"},"datePublished":"2014-05-06T10:37:08+03:00","dateModified":"2026-10-06T06:29:26+03:00"},{"@type":"WebSite","@id":"https:\/\/farmacija-mic.lv\/en\/#website","url":"https:\/\/farmacija-mic.lv\/en\/","name":"Medikamentu Inform\u0101cijas Centrs","description":"Farm\u0101cijas nozares port\u0101ls farmaceitiem un \u0101rstiem. Zi\u0146as, normat\u012bvie akti, pas\u0101kumi un t\u0101l\u0101kizgl\u012bt\u012bba vienuviet kop\u0161 2001. gada.","inLanguage":"en-US","publisher":{"@id":"https:\/\/farmacija-mic.lv\/en\/#organization"}}]},"og:locale":"en_US","og:site_name":"Medikamentu Inform\u0101cijas Centrs","og:type":"article","og:title":"\u201cGrindeks\u201d apgroz\u012bjums p\u0113rn audzis par 1% - Medikamentu Inform\u0101cijas Centrs","og:description":"AS &quot;Grindeks&quot; 30.apr\u012bl\u012b &quot;NASDAQ OMX Riga&quot; bir\u017e\u0101 iesniegtie 2013.gada revid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna apgroz\u012bjums p\u0113rn bijis 118,5 miljoni eiro, kas ir par 0,8 miljoniem eiro jeb par 1% vair\u0101k k\u0101 2012. gad\u0101. Koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2013. gad\u0101 bijusi 13,4 miljoni eiro, zi\u0146o uz\u0146\u0113muma p\u0101rst\u0101vji.Bruto pe\u013c\u0146as rentabilit\u0101te 2013.","og:url":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/","og:image":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Grindex-logo.jpg","og:image:secure_url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Grindex-logo.jpg","og:image:width":660,"og:image:height":330,"article:published_time":"2014-05-06T08:37:08+00:00","article:modified_time":"2026-10-06T03:29:26+00:00","twitter:card":"summary_large_image","twitter:title":"\u201cGrindeks\u201d apgroz\u012bjums p\u0113rn audzis par 1% - Medikamentu Inform\u0101cijas Centrs","twitter:description":"AS &quot;Grindeks&quot; 30.apr\u012bl\u012b &quot;NASDAQ OMX Riga&quot; bir\u017e\u0101 iesniegtie 2013.gada revid\u0113tie finan\u0161u p\u0101rskati liecina, ka koncerna apgroz\u012bjums p\u0113rn bijis 118,5 miljoni eiro, kas ir par 0,8 miljoniem eiro jeb par 1% vair\u0101k k\u0101 2012. gad\u0101. Koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2013. gad\u0101 bijusi 13,4 miljoni eiro, zi\u0146o uz\u0146\u0113muma p\u0101rst\u0101vji.Bruto pe\u013c\u0146as rentabilit\u0101te 2013.","twitter:image":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/Grindex-logo.jpg"},"aioseo_meta_data":{"post_id":"370","title":null,"description":null,"keywords":null,"keyphrases":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_custom_url":null,"og_image_custom_fields":null,"og_image_url":null,"og_image_width":null,"og_image_height":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_image_url":null,"twitter_title":null,"twitter_description":null,"schema_type":"default","schema_type_options":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"limit_modified_date":false,"ai":null,"breadcrumb_settings":null,"seo_analyzer_scan_date":null,"created":"2026-09-23 01:07:55","updated":"2026-10-07 11:35:04"},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/farmacija-mic.lv\/en\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/farmacija-mic.lv\/category\/statistika\/\" title=\"Statistika\">Statistika<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t\u201cGrindeks\u201d apgroz\u012bjums p\u0113rn audzis par 1%\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/farmacija-mic.lv\/en\/"},{"label":"Statistika","link":"https:\/\/farmacija-mic.lv\/category\/statistika\/"},{"label":"&#8220;Grindeks&#8221; apgroz\u012bjums p\u0113rn audzis par 1%","link":"https:\/\/farmacija-mic.lv\/en\/grindeks-apgrozijums-pern-audzis-par-1\/"}],"_links":{"self":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/comments?post=370"}],"version-history":[{"count":1,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/370\/revisions"}],"predecessor-version":[{"id":2101,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/370\/revisions\/2101"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/media\/11814"}],"wp:attachment":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/media?parent=370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/categories?post=370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/tags?post=370"},{"taxonomy":"mic_flag","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/mic_flag?post=370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}